Prognostic model based on the geriatric nutritional risk index and sarcopenia in patients with diffuse large B-cell lymphoma

Systemic inflammation and cachexia are associated with adverse clinical outcomes in diffuse large B-cell lymphoma (DLBCL). The Geriatric Nutritional Risk Index (GNRI) is one of the main parameters used to assess these conditions, but its efficacy in DLBCL is inconclusive. We retrospectively reviewed...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	BMC cancer 2020-05, Vol.20 (1), p.439-10, Article 439
Hauptverfasser:	Go, Se-Il, Kim, Hoon-Gu, Kang, Myoung Hee, Park, Sungwoo, Lee, Gyeong-Won
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Aged Aged, 80 and over Albumin Anthracyclines Antineoplastic Combined Chemotherapy Protocols - therapeutic use B-cell lymphoma Body mass index Body weight Cachexia Cancer Care and treatment Chemotherapy Corticosteroids Cyclophosphamide Cyclophosphamide - administration & dosage Doxorubicin Doxorubicin - administration & dosage Drug dosages Female Follow-Up Studies Geriatrics Humans Lymphocytes B Lymphoma Lymphoma, large B-cell, diffuse Lymphoma, Large B-Cell, Diffuse - drug therapy Lymphoma, Large B-Cell, Diffuse - pathology Male Malnutrition Medical prognosis Middle Aged Models, Statistical Monoclonal antibodies Mortality Muscles Musculoskeletal system Non-Hodgkin's lymphomas Nutrition Assessment Nutritional Status Patients Prednisone Prednisone - administration & dosage Prognosis Retrospective Studies Rituximab Rituximab - administration & dosage Sarcopenia Sarcopenia - chemically induced Sarcopenia - epidemiology Sarcopenia - pathology Serum albumin Skeletal muscle Survival Rate Targeted cancer therapy Variables Vincristine Vincristine - administration & dosage Young Adult
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Systemic inflammation and cachexia are associated with adverse clinical outcomes in diffuse large B-cell lymphoma (DLBCL). The Geriatric Nutritional Risk Index (GNRI) is one of the main parameters used to assess these conditions, but its efficacy in DLBCL is inconclusive. We retrospectively reviewed 228 DLBCL patients who were treated with R-CHOP immunochemotherapy (rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone). The patients were stratified according to GNRI score (> 98, 92 to 98, 82 to
ISSN:	1471-2407 1471-2407
DOI:	10.1186/s12885-020-06921-2